Journey Medical Corporation (Nasdaq: DERM) exhibited at the 2025 American Academy of Dermatology (AAD) Annual Meeting. The event was scheduled for March 7-11, 2025, in Orlando, Florida.
Highlighting Emrosi™: A New Rosacea Treatment.
At booth 2181, Journey Medical presented Emrosi™, their latest FDA-approved treatment for inflammatory lesions of rosacea in adults. The FDA granted approval for Emrosi™ in November 2024.
Leadership’s Perspective.
Claude Maraoui, Co-Founder, President, and CEO of Journey Medical, expressed enthusiasm about the event. He emphasized the opportunity to educate the dermatology community about Emrosi™. Maraoui highlighted that Emrosi™ is the lowest-dose oral minocycline available. It has shown superior clinical outcomes for rosacea compared to placebo and Oracea®, while maintaining a comparable safety profile.
About the AAD Annual Meeting.
The AAD Annual Meeting is a premier dermatology conference in the United States. It features over 350 exhibitors and attracts nearly 20,000 attendees, including more than 10,000 medical professionals. The conference offers over 300 educational sessions. Founded in 1938 and based in Rosemont, Illinois, the AAD is dedicated to advancing dermatological care and education.
Important Safety Information for Emrosi™.
- Indication: Emrosi™ is indicated for treating inflammatory lesions (papules and pustules) of rosacea in adults.
- Adverse Events: The most common adverse reaction, reported by ≥1% of subjects treated with Emrosi™ and more frequently than in subjects receiving placebo, was dyspepsia.
- Contraindications: Emrosi™ should not be taken by patients with a history of hypersensitivity to any tetracyclines.
- Warnings/Precautions: Serious skin reactions, including anaphylaxis and DRESS syndrome, have been reported with minocycline use. If DRESS syndrome is recognized, discontinue Emrosi™ immediately. Use during the second and third trimesters of pregnancy, infancy, and childhood up to the age of 8 years may cause permanent tooth discoloration and reversible inhibition of bone growth. Discontinue Emrosi™ if antibiotic-associated colitis or liver injury is suspected. Patients experiencing light-headedness, dizziness, or vertigo should be cautioned about driving or operating heavy machinery.
